QR Code

Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies

Abstract Introduction Two phase 3 trials (TRuE-V1 and TRuE-V2) demonstrated that a topical formulation of the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved repigmentation versus vehicle cream in adolescent and adult patients with vitiligo. This post hoc analysis of pooled TR...

Full description

Saved in:
Main Authors: Julien Seneschal, Albert Wolkerstorfer, Seemal R. Desai, Pearl Grimes, Khaled Ezzedine, Amit G. Pandya, Deanna Kornacki, Shaoceng Wei, Thierry Passeron, David Rosmarin
Format: Artigo
Language:Inglês
Published: Adis, Springer Healthcare 2025-03-01
Series:Dermatology and Therapy
Subjects:
JAK inhibitor
Janus kinase
Repigmentation
Ruxolitinib cream
Topical
Vitiligo
Online Access:https://doi.org/10.1007/s13555-025-01381-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items